# Semaglutide Dose & Dosage: What the Trials and Label Document

> Semaglutide dose and dosage as documented in the trials and approved label: the once-weekly subcutaneous titration, the oral schedule, and the one-week half-life. Not advice.

The titration schedules, routes and half-life documented in the published trials and approved labeling — third person, no recommendations.

## Read this first

This page describes the semaglutide dose schedules that appear in the published trials and the approved label. It is a record of what was studied and approved, written in the third person. It is not a recommendation, and it contains no instruction for any individual to take any amount. Semaglutide is a prescription medicine; dosing decisions belong to a prescriber. The pattern across trials is consistent: the drug is started low and stepped up slowly over weeks, because that titration is what keeps the early gut side effects manageable. The injected form is given once a week; the tablet form is taken once a day on a strictly empty stomach. Below are the documented numbers — the climbing-dose schedules, the routes studied, and the roughly one-week half-life that makes once-weekly injection possible — each tied to its source.

## Semaglutide dose: the subcutaneous schedule studied

In the trials and label, the injected (subcutaneous) semaglutide dose is escalated, not started at target. For chronic weight management the documented schedule climbs once weekly: 0.25 mg for weeks 1-4, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching a 2.4 mg maintenance dose — the dose used in STEP 1 [1] and SELECT [3]. For type 2 diabetes the documented maintenance doses are lower: 0.25 mg to start, then 0.5 mg, then 1.0 mg, with a 2.0 mg option studied in the SUSTAIN program. The reason for the slow climb is tolerability: a pooled analysis of the weight-management program found the gastrointestinal events were predominantly mild-to-moderate, transient, and concentrated during exactly this escalation period [23]. The figures here are study- and label-attributed and are not a personal dosing plan.

## Semaglutide dosage: oral semaglutide and its fasted rule

The oral semaglutide dosage runs on a different track. The tablet is co-formulated with an absorption enhancer, SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises local stomach pH to help the peptide cross — but oral bioavailability is still only about 0.4-1%, so administration is unforgiving [18]. The documented diabetes schedule is 3 mg daily for 30 days, then 7 mg, then 14 mg daily, taken on an empty stomach about 30 minutes before the first food, drink or other oral medicine, with no more than ~120 mL of water [18]. Higher oral doses have been studied for obesity and diabetes: 25 mg and 50 mg once daily in the OASIS and PIONEER PLUS programs, with the higher doses improving glycemic control and weight versus 14 mg [11]. The strict fasted rule is the practical heart of any oral semaglutide dosage: get it wrong and the absorbed amount drops sharply.

## Semaglutide injection: route and handling

The classic semaglutide injection is a once-weekly subcutaneous dose, the route used across the SUSTAIN, STEP and SELECT programs [1][2][3]. Subcutaneous means into the fatty layer just under the skin rather than into a vein or muscle. On handling: per the approved labeling, pre-filled pens are typically stored refrigerated (2-8 C) before first use and may then be kept at room temperature (<=30 C) for a defined in-use period, commonly cited as up to 56 days. Reconstituted research preparations are generally kept at 2-8 C and used within about 28 days. These storage details are label- and protocol-attributed and describe the manufactured product; they are not instructions for use.

## Half-life and clearance

Semaglutide's elimination half-life is approximately one week — commonly cited as ~165-168 hours — for both the subcutaneous and oral forms, with effectively complete clearance roughly five weeks after the final dose [17]. The long half-life is structural: strong, reversible binding to albumin via the C18 fatty di-acid side chain, plus DPP-4 resistance from the position-8 substitution, together keep the molecule circulating for days rather than minutes. Two practical consequences follow from the published record. First, once-weekly injection is feasible because levels stay steady between doses. Second, the drug lingers: label guidance ties the multi-week washout advised before a planned pregnancy directly to this half-life arithmetic [17]. Drug-interaction studies are reassuring — no clinically relevant effect on metformin, warfarin, atorvastatin or digoxin exposure despite slowed gastric emptying [12].

---

A naturalist's field notebook on the semaglutide trial record — observed, sequenced, and cited; not a clinic, not a prescriber, not a vendor.